Neratinib derivative 7A induces apoptosis in colon cancer cells via the p53 pathway
Zhi-Yu Liu1, Ruo-Tong Liu1, Wen-Hao Cheng1
1College of Pharmacy, Jiangsu Ocean University, Lianyungang 222000, China.
Abstract:
Colorectal cancer remains a significant health threat, with its incidence continuously rising, underscoring the urgent need for the development of new therapeutic agents. In our previous research, we identified 7A, a derivative of Neratinib, as having pronounced antitumor activity. However, its specific effects and mechanisms in colorectal cancer have not been thoroughly investigated. Therefore, this study employed in vivo and in vitro experiments, utilizing techniques such as RNA sequencing, Western blotting, and PCR, to provide a comprehensive analysis of 7A's mechanism of action in colorectal cancer. The results indicate that 7A induces DNA damage and activates the P53 pathway, thereby promoting apoptosis in colorectal cancer cells. Additionally, 7A treatment significantly reduced angiogenesis and tumor weight. Our findings suggest that 7A, a Neratinib derivative, holds promise as a novel candidate for colorectal cancer therapy.
Insights
A Neratinib derivative, 7A, shows promise for colorectal cancer treatment by inducing DNA damage and apoptosis. This compound also reduced tumor growth and angiogenesis, highlighting its therapeutic potential.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Colorectal cancer (CRC) incidence is rising, necessitating novel therapeutic strategies.
- Neratinib derivative 7A demonstrated prior antitumor activity, but its CRC-specific mechanisms were unknown.
Purpose of the Study:
- To comprehensively investigate the mechanism of action of Neratinib derivative 7A in colorectal cancer.
- To evaluate the efficacy of 7A in preclinical colorectal cancer models.
Main Methods:
- In vivo and in vitro experiments were conducted.
- Key techniques included RNA sequencing, Western blotting, and Polymerase Chain Reaction (PCR).
Main Results:
- 7A induced significant DNA damage in colorectal cancer cells.
- Activation of the P53 pathway and subsequent apoptosis were observed.
- 7A treatment led to reduced angiogenesis and decreased tumor weight.
Conclusions:
- Neratinib derivative 7A effectively promotes apoptosis in colorectal cancer cells.
- 7A exhibits anti-angiogenic properties and suppresses tumor growth.
- 7A represents a promising therapeutic candidate for colorectal cancer treatment.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity
02:23Abnormal Proliferation
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...